Monday, 5 December 2011
Poster Hall (Cancún Center)
Raúl Lázaro Castro Almarales, MD
,
National Center of Bioproducts (BIOCEN), WAO Member, Cuban Society of Allergy Member, Cuban Society of Immunology Member, Cuban Society of Family Medicine Member, Mayabeque, Cuba
Mercedes Ronquillo, MD
,
Allergy Service, Univesity Hospital General Calixto García, WAO Member, Cuban Society of Allergy Member, Cuban Society of Immunology Member, Havana, Cuba
Mirta Alvarez Castello, MD
,
Allergology Department, University Hospital General Calixto García, WAO Member, Cuban Society of Allergy , Asthma and Clinical Immunology, Member, Cuban Society of Immunology Member, Havana, Cuba
José Rodríguez, MD
,
Univesity Hospital General Calixto García, WAO Member, Cuban Society of Allergy Member, Cuban Society of Immunology Member, Havana, Cuba
Mayda González, MD
,
Docent Policlinic Pedro Fonseca, Cuban Society of Family Medicine Member, Cuban Society of Allergy Member, Cuban Society of Immunology, Havana, Cuba
Alexis Labrada, PhD
,
Allergen Department, WAO Member. Cuban Society of Inmunology. Cuban Society of Allergy., Mayabeque, Cuba
Bárbara I Navarro Viltres, MD
,
Cuban Society of Allergy Member, Cuban Society of Immunology, Havana, Cuba
Yunia Oliva Díaz, Lic.
,
Member of Cuban Society of Immunology, Maya, Cuba
Maytee Mateo
,
Member of Cuban Society of Immunology, Mayabeque, Cuba
Background: Allergen-specific subcutaneous immunotherapy (SCIT) is presently recognized as a biological response modifier, as it is the only available treatment ,able to influence the natural course of allergic disease. Extensive clinical evidence supports its efficacy. Safety concerns are related to the risks of anaphylactic reactions during treatment. Standardization of allergen vaccines in terms of allergenic activity allows a more precise control over the administered doses and can be, therefore, very relevant for both efficacy and safety of SCIT. House Dust Mites (HDM), particularly
Dermatophagoides pteronyssinus (Dp), Dermatophagoides siboney (Ds) and
Blomia tropicalis (Bt) have been described as very relevant allergen sources in Cuba, with a strong association to respiratory allergy symptoms.
Objetive: To asses the efficacy and safety of standardized allergen vaccines of these three mite species (VALERGEN, BIOCEN, Cuba), in Cuban asthmatic patients.
Methods: Three Double-Blind Placebo-Controlled clinical trials were performed in 40 patients each, showing asthmatic symptoms and positive predominant Skin Prick Test (SPT) to each mite, respectively. Half of patients received the active treatment consisting of subcutaneous injections with increasing doses, up to 6000 BU.
Results: The total 1 year cumulative dose was 63035 BU, in an average of 20.5 injections. The treatment was effective in the reduction of clinical symptoms (up to 32%, 95%CI:28-36%; p=0.0006) and medication intake (23%, 95%CI:18-28%), as compared to control treatment. The skin sensitivity to the allergens decreased significantly (p=0.0001), with regard to the beginning of the treatment. The allergen amount needed to induce a positive SPT increased 297-fold. An improvement of the lung function was observed, expressed in a modest Peak-Expiratory-Flow increase (p<0.05) and reduction of PEF daily variability. SIT was considered effective in 71% of patients. The frequency of local adverse reactions was 2.4 % of injections.
Conclusions:
The results indicates that immunotherapy, using standardized House Dust Mite vaccines, including tropical species, is effective and safe for the control and amelioration of the asthma in our population.
